Use of PD-1 (PDCD1) inhibitors for the treatment of Richter syndrome: experience at a single academic centre

Br J Haematol. 2019 Apr;185(2):363-366. doi: 10.1111/bjh.15508. Epub 2018 Jul 20.

Authors

Kerry A Rogers¹, Ying Huang¹, Emily Dotson², Jordan Lundberg², Leslie A Andritsos¹, Farrukh T Awan¹, Jennifer A Woyach¹, John C Byrd¹

Affiliations

¹ Division of Hematology, The Ohio State University, Columbus, OH, USA.
² Department of Pharmacy, The Ohio State University, Columbus, OH, USA.

PMID: 30028000
DOI: 10.1111/bjh.15508

No abstract available

Keywords: PD-1 (PDCD1) inhibitors; Richter syndrome; chronic lymphocytic leukaemia; immune checkpoint inhibitors.

MeSH terms

Aged
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Agents, Immunological / therapeutic use*
Female
Humans
Kaplan-Meier Estimate
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Lymphoma, Large B-Cell, Diffuse / drug therapy*
Male
Middle Aged
Nivolumab / therapeutic use
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
Syndrome
Treatment Failure

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
PDCD1 protein, human
Programmed Cell Death 1 Receptor
Nivolumab
pembrolizumab